title: Goserelin--depot preparation of LHRH analogue used in the treatment of endometriosis.
abstract: In summary then, Zoladex depot (Goserelin 3.6 mg) administered monthly for a period of six months proved highly efficacious in achieving endocrine parameters of pituitary desensitization and hypo-oestrogenism. Initial studies treating symptomatic patients with endometriosis shows satisfactory relief of symptoms and significant impact on the disease process as shown by resolution or reduction in number and size of disease deposits. The depot can be given as a subcutaneous injection without the need of local anaesthesia and its duration of action is 28 days. Zoladex depot should offer a suitable, acceptable form of treatment for patients with endometriosis.
authors: Royal Free Hospital School of Medicine, London.
authors: R W
authors: RW
authors: Shaw
mesh_terms: D002064:Buserelin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002626:Chemistry, Pharmaceutical; D003692:Delayed-Action Preparations; D004702:Endocrine Glands / Q000187:drug effects / Q000503:physiopathology; D004715:Endometriosis / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D017273:Goserelin; D006801:Humans; D015337:Multicenter Studies as Topic; D012449:Safety
chemical_list: D003692:Delayed-Action Preparations; D017273:Goserelin; D002064:Buserelin